BioMarin Director Ho Maykin Receives 7,490 Restricted Stock Units

BioMarin Pharmaceutical Inc. director Ho Maykin received 7,490 restricted stock units on June 2, 2026, as reported in this Form 4 filing. The transaction was coded as an award of equity securities (Code A) with a price of $0 per share, which is typical for restricted stock unit grants. Following this award, Maykin's total holdings in BioMarin common stock increased to 35,500 shares. The filing notes that these are restricted stock units granted on June 2, 2026, and the price is not applicable. The filing was signed by attorney-in-fact Tae Sang Yoo on June 4, 2026. This represents a standard equity compensation award to a company director as part of their compensation package.